학술논문
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Document Type
Article
Author
Pignata, Sandro; Oza, Amit; Hall, Geoff; Pardo, Beatriz; Madry, Radoslaw; Cibula, David; Klat, Jaroslav; Montes, Ana; Glasspool, Rosalind; Colombo, Nicoletta; Pete, Imre; Herrero Ibáñez, Ana; Marín, Margarita Romeo; Ilieva, Rumyana; Timcheva, Constanta; Di Maio, Massimo; Blakeley, Christopher; Taylor, Rosie; Barnicle, Alan; Clamp, Andrew
Source
Subject
*OVARIAN cancer
*GENETIC mutation
*BRCA genes
*HEREDITARY nonpolyposis colorectal cancer
*OLAPARIB
*CANCER prognosis
*
*
*
*
*
Language
ISSN
0090-8258
Abstract
The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after ≥2 lines of treatment. Patients received maintenance olaparib capsules (400 mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort. The co-primary endpoints were investigator-assessed progression-free survival (PFS; modified Response Evaluation Criteria in Solid Tumors v1.1) in BRCAm and sBRCAm cohorts. Secondary endpoints included health-related quality of life (HRQoL) and tolerability. 177 patients received olaparib. At the primary data cut-off (17 April 2020), the median follow-up for PFS in the BRCAm cohort was 22.3 months. The median PFS (95% CI) in BRCAm, sBRCAm, gBRCAm and non-BRCA HRRm cohorts was 18.0 (14.3–22.1), 16.6 (12.4–22.2), 19.3 (14.3–27.6) and 16.4 (10.9–19.3) months, respectively. Most patients with BRCAm reported improvements (21.8%) or no change (68.7%) in HRQoL and the safety profile was as expected. Maintenance olaparib had similar clinical activity in PSR OC patients with sBRCAm and those with any BRCAm. Activity was also observed in patients with a non-BRCA HRRm. ORZORA further supports use of maintenance olaparib in all patients with BRCA-mutated, including sBRCA-mutated, PSR OC. • Clinical activity of maintenance olaparib in platinum-sensitive relapsed ovarian cancer was seen with any BRCA mutation. • This included activity in patients with somatic BRCA mutations. • Activity was also seen in patients with non-BRCA homologous recombination repair mutations. • Safety and tolerability were consistent with previous studies in this setting. [ABSTRACT FROM AUTHOR]